help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ropert, J. F.
Right arrow Articles by Yen, S. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ropert, J. F.
Right arrow Articles by Yen, S. S.

Journal of Clinical Endocrinology & Metabolism, Vol 52, 583-585, Copyright © 1981 by Endocrine Society

ARTICLES

Endogenous opiates modulate pulsatile luteinizing hormone release in humans

JF Ropert, ME Quigley and SS Yen

To test the postulate that endogenous opioid peptides may be involved in the neuroendocrine mechanisms controlling the frequency and amplitude of LH pulses, saline and an opioid receptor antagonist, naloxone, were infused sequentially, each for 6-h intervals, in six normal cycling women during the luteal phase of the menstrual cycle. During naloxone infusion (1.6 mg/h), there was a significant (P less than 0.01) increase in both the frequency and amplitude of LH pulses compared to those in saline controls. FSH pulses were not discernible in individual subjects; however, a significant increment in FSH levels occurred concomitantly with the increase in LH. These data strongly suggest that endogenous opiates, through an inhibition of hypothalamic LRF, participate in the endocrine events leading to the low frequency of episodic LH secretion characteristic of the luteal phase of the human menstrual cycle.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
R. F. Casper and M. F. M. Mitwally
Aromatase Inhibitors for Ovulation Induction
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 760 - 771.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. Dudas and I. Merchenthaler
Topography and Associations of Leu-Enkephalin and Luteinizing Hormone-Releasing Hormone Neuronal Systems in the Human Diencephalon
J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1842 - 1848.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. R. Smith, J.-K. Zubieta, M. G. del Carmen, R. F. Dannals, H. T. Ravert, H. A. Zacur, and J. J. Frost
Brain Opioid Receptor Measurements by Positron Emission Tomography in Normal Cycling Women: Relationship to Luteinizing Hormone Pulsatility and Gonadal Steroid Hormones
J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4498 - 4505.
[Abstract] [Full Text]

Home page
 Reproductive SciencesHome page
A. J. Rapkin, D. Shoupe, A. Reading, K. K. Daneshgar, L. Goldman, Y. Bohn, D. W. Brann, and V. B. Mahesh
Decreased Central Opioid Activity in Premenstrual Syndrome: Luterinizing Hormone Response to Naloxone
Reproductive Sciences, March 1, 1996; 3(2): 93 - 98.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1981 by The Endocrine Society